PureTech Health PLC PRTC

BOSTON, September 30, 2026--Celea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical Trials at the IPF Summit

PureTech Health PLC (PTCHF) ended H1 2026 with $220 million in cash, cut go-forward burn to $30--$40 million annually, and is running ahead of its target of three concept-stage programs per year.

PureTech Health (NASDAQ:PRTC) outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory progress at Gallop Oncology, and a strategy centered on earlier external funding for its founded entit

BOSTON, September 21, 2026--PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced the successful completion of the End-of-Phase 1 (EOP1) meeting with the U.S. Food and Drug Administration (FDA) and the receipt of FDA Fast Track designation for LYT-200 in combination with a hypomethylating agent (HMA) for the treatment of relapsed/refractory (R/R) high-risk

BOSTON, September 09, 2026--PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers

BOSTON, August 25, 2026--PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

BOSTON, August 25, 2026--Celea Therapeutics Will Present Phase 3 Trial Design for IPF & Key Insights from a Deupirfenidone Drug-Drug Interaction Study at ERS

BOSTON, July 13, 2026--PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of IPF

The trial is expected to begin in early third quarter of 2026.

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.

BOSTON, July 02, 2026--Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat IPF

BOSTON, July 02, 2026--PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to IPF

BOSTON, June 10, 2026--PureTech Health: Results of Annual General Meeting

BOSTON, June 09, 2026--PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™

The Boston-based biotech sold more stock than originally planned at $18 a share, giving it a market value of $1.1 billion

PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) told investors that its founded entity Seaport Therapeutics has priced an upsized US initial public offering at the top of its target range, putting the clinical-stage neuropsychiatry company on course to raise gross proceeds of $254.9...

PureTech Health (NASDAQ:PRTC) used its annual results call to outline a refined operating strategy centered on a leaner corporate structure, earlier formation of “founded entities,” and an increased emphasis on returning capital to shareholders when significant inflows occur. Chief Executive Office